Moss Adams Wealth Advisors LLC Has $640,000 Position in Pfizer Inc. (NYSE:PFE)

Moss Adams Wealth Advisors LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 5.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,111 shares of the biopharmaceutical company’s stock after acquiring an additional 1,141 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Pfizer were worth $640,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. KMG Fiduciary Partners LLC bought a new position in shares of Pfizer during the third quarter worth $2,891,000. Stratos Investment Management LLC lifted its holdings in Pfizer by 15.6% during the third quarter. Stratos Investment Management LLC now owns 14,928 shares of the biopharmaceutical company’s stock worth $432,000 after acquiring an additional 2,013 shares in the last quarter. Stratos Wealth Advisors LLC increased its holdings in shares of Pfizer by 0.6% in the third quarter. Stratos Wealth Advisors LLC now owns 111,559 shares of the biopharmaceutical company’s stock worth $3,229,000 after acquiring an additional 621 shares in the last quarter. D. Scott Neal Inc. bought a new stake in shares of Pfizer in the third quarter worth about $203,000. Finally, Stratos Wealth Partners LTD. raised its position in shares of Pfizer by 11.6% during the third quarter. Stratos Wealth Partners LTD. now owns 290,370 shares of the biopharmaceutical company’s stock worth $8,403,000 after purchasing an additional 30,107 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 0.1 %

Shares of Pfizer stock opened at $29.23 on Friday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business’s 50 day moving average is $29.07 and its 200-day moving average is $28.44. The stock has a market cap of $165.64 billion, a P/E ratio of -63.54, a P/E/G ratio of 1.02 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.67 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 5.75%. Pfizer’s dividend payout ratio is -365.21%.

Analyst Upgrades and Downgrades

Several analysts have commented on PFE shares. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Thursday, October 3rd. Barclays lifted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday. They set a “market perform” rating and a $32.00 price objective for the company. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.